BEIJING, Sept. 30,
2022 /PRNewswire/ -- Concord Medical Services
Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM),
a healthcare provider specialized in cancer treatment, research,
education and prevention by establishing proton centers and cancer
hospitals and operating an extensive network of radiotherapy and
diagnostic imaging centers in China, today announced changes in its
Mr. Yaw Kong Yap has stepped down
from his role as the chief financial officer and president of the
Company due to reaching retirement age, effective from September 30, 2022. Mr. Yap will continue to
advise the Company going forward. Mr. Boxun Zhang, who previously
served as an independent director of the Company, agreed to be and
was appointed as the successor chief financial officer, effective
from September 30, 2022.
The Company received a letter of resignation from each of Mr.
Boxun Zhang and Dr. Weibo Yin, both
notifying the Company of his resignation as an independent director
of the Company and all his positions in the board of directors of
the Company (the "Board") and its relevant committees for personal
reasons not resulting from any disagreement with the Company on any
matter relating to the Company's operations, policies or practice,
effective from September 29,
Mr. Wayne Yu agreed to be and was appointed as a new
independent director to serve on the Board, effective from
September 30, 2022. Mr. Wayne Yu
was also appointed to serve as a member and chairman of the audit
committee of the Board and a member of the compensation committee
of the Board. Mr. Hongzhong Liu
agreed to be and was appointed as a new independent director to
serve on the Board, effective from September
30, 2022. Mr. Hongzhong Liu
was also appointed to serve as a member of the audit committee of
the Board. Biographical information relating to Mr. Wayne Yu
and Mr. Hongzhong Liu is set out as
Wayne Yu has served as a
professor at City University of Hong
Kong since March 2015. Prior
to that, Mr. Yu worked at The Hong Kong Polytechnic University from
September 1999 to February 2015, and at Queen's University from
July 1998 to August 1999. In addition, Mr. Yu serves as an
independent director for a number of companies listed in
Hong Kong and mainland
China. He is a CFA® charterholder
and a member of the Honorary Advisory Panel to the Financial
Reporting Council (FRC), a statutory regulatory body for auditors
of listed companies in Hong Kong.
He received his Ph.D. in finance from University of Alberta in November 1997.
Mr. Hongzhong Liu
has served as a professor at Shanghai International Studies
University since January 2020. Mr.
Liu is the vice president of China Society of World Economics and
the vice executive secretary of Chinese Association of Asia-Pacific
Studies. He served as the dean of School of International Studies
of Liaoning University from
March 2012 to October 2019, and served various teaching
positions at Liaoning University
since July 1999. Mr. Liu was a
visiting scholar at George Washington
University from January 2015
to June 2015, at Washington University in St. Louis from August
2007 to July 2008, and at KDI
School of Public Policy and Management August 2001 to July
2002. He has published numerous books and articles, and
presided over 15 important projects including a major project
supported by National Social Science Fund of China. He received his Ph.D. in world
economics from Liaoning University
in June 1999.
The Company received a letter of resignation from Dr.
Matthew D. Callister, notifying the
Company of his resignation as the chief medical officer of the
Company for personal reasons not resulting from any disagreement
with the Company on any matter relating to the Company's
operations, policies or practice, effective from September 30, 2022.
"We would like to express our sincere gratitude to our
managements, Mr. Yaw Kong Yap and
Dr. Matthew D. Callister, and our
independent directors, Mr. Boxun Zhang and Dr. Weibo Yin, for all the efforts and contributions
over the past years," commented Dr. Jianyu
Yang, chairman and chief executive officer of the Company.
"In the meantime, we are pleased to announce the appointments of
Mr. Boxun Zhang as our chief financial officer and Mr.
Wayne Yu and Mr. Hongzhong Liu
as our independent directors. Each of them brings a wealth of
professional knowledge and expertise to Concord Medical. We look
forward to working closely with them to continue to create value
for our shareholders."
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider featuring a full cycle of premium oncology services
including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in
all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as
the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its
network of self-owned cancer hospitals and clinics as well as
partnered hospitals across China.
For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable law.
SOURCE Concord Medical Services Holdings Limited